Previous 10 | Next 10 |
2023-07-18 06:22:03 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The biotech industry is constantly evolving due to being on the cutting edge of the healthcare industry’s research and development. Large biotech companies such as Johnson and Johnso...
2023-07-14 10:01:23 ET Gainers: PainReform ( PRFX ) +112% . Acadia Pharmaceuticals ( ACAD ) +15% . Nutriband ( NTRB ) +14% . Arcturus Therapeutics ( ARCT ) +10% . Exicure ( XCUR ) +7% . Losers: Theseus Pharmaceuticals ( ...
2023-06-26 13:40:30 ET Summary Arcturus Therapeutics is developing mRNA medicines and vaccines for infectious diseases and rare disorders, with a focus on their ARCT-810 candidate for ornithine transcarbamylase deficiency. The company reported strong Q1 2023 financial results, wit...
2023-06-15 17:38:38 ET Gainers: Adobe ( ADBE ) +5% . Arcturus Therapeutics ( ARCT ) +5% . Xeris Biopharma Holdings ( XERS ) +4% . Castle Biosciences ( CSTL ) +4% . Enovix Corporation ( ENVX ) +4% . Losers: Mil...
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today ann...
2023-05-12 17:45:30 ET Gainers: GSI Technology ( GSIT ) +16% . Telos ( TLS ) +8% . Arcturus Therapeutics Holdings ( ARCT ) +5% . Atara Biotherapeutics ( ATRA ) +4% . Health Catalyst ( HCAT ) +4% . Losers: Zapp Electric Ve...
2023-05-11 10:00:13 ET Gainers: Organogenesis ( ORGO ) +23% . Arcturus Therapeutics ( ARCT ) +14% . Phathom Pharmaceuticals ( PHAT ) +14% . Pulse Biosciences ( PLSE ) +13% . PharmaCyte Biotech ( PMCB ) +11% . Losers: ImmunityBi...
2023-05-11 08:21:38 ET Arcturus Therapeutics ( NASDAQ: ARCT ) added ~3% pre-market Thursday after H.C. Wainwright upgraded the biotech to Buy from Neutral, raising its price target to $51 from $19 per share on the potential of its COVID-19 vaccine ARCT-154. In November, Arct...
2023-05-09 22:05:23 ET Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants Neda Safarzadeh – Vice President, Head-Investor Relations, Public Relations and Marketing Joseph Payne – Presi...
2023-05-09 16:05:22 ET Arcturus Therapeutics press release ( NASDAQ: ARCT ): Q1 GAAP EPS of $1.87 beats by $1.46 . Revenue of $80.29M (+1432.3% Y/Y) beats by $30.83M . For further details see: Arcturus Therapeutics GAAP EPS of $1.87 beats by $1.46, revenu...
News, Short Squeeze, Breakout and More Instantly...
Arcturus Therapeutics Ltd. Company Name:
ARCT Stock Symbol:
NASDAQ Market:
Arcturus Therapeutics Ltd. Website:
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, toda...
2024-07-02 10:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for ARCT on July 2, 2024 08:19AM ET. The previous analyst recommendation was Overweight. ARCT was trading at $23.66 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
ARCT-810 Phase 2 study completed enrollment at 0.3 mg/kg dose level in Europe with data expected later this year ARCT-810 to expand Phase 2 clinical program in the U.S. to enroll patients with more severe disease ARCT-032 IND for Phase 2 multiple ascending dose study to be submitt...